The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting a recalibration of growth prospects within the med-tech sector, UBS has lowered its price target for ResMed from $312 to $300. This adjustment was primarily driven by valuation concerns, although the bank maintained its 'Buy' rating on the stock. Analysts suggest that the company remains well-positioned for robust earnings growth fueled by rising sales and margin expansion, implying the stock remains undervalued despite the lower target.
This action by UBS follows similar pressure in the sector, as RBC Capital Markets recently downgraded the stock, reflecting growing analyst caution toward medical device manufacturers. However, ResMed's latest earnings reports showed a 7% revenue increase in the previous quarter according to company filings, supporting UBS's relative optimism compared to peers facing supply chain headwinds.
Regarding market performance, ResMed (ticker 0KW4.L) stood at $197.79 at the close of July 20, 2026, with a daily range between $194.52 and $200.36. Investors are now looking toward broader macroeconomic catalysts that could impact healthcare sector sentiment, including the Bank of Canada’s Monetary Policy Report and interest rate decision scheduled for July 15, 2026, which may influence global market volatility.